What is the future of treatment de-escalation for HPV-positive oropharyngeal cancer? A review of ongoing clinical trials.

ABSTRACT:

Background

Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has increased in incidence in recent decades. With higher cure rates in younger populations, long-term survivors may live with acute- and long-term toxicity, leading to increased interest in de-escalation treatment strategies for HPV-related OPSCC. Herein, we have examined the current landscape of clinical trials in this context.

Methods

A review of active clinical trials related to de-escalation of HPV-associated OPSCC treatment was performed using the clinicaltrials.gov database from inception to January 2022. A search using the key words "oropharyngeal cancer" and "HPV" was completed. Three investigators independently reviewed each trial, with any discrepancies settled by a four

SUBMITTER: Mensour EA 

PROVIDER: S-EPMC9816564 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature